Page last updated: 2024-10-30

lamotrigine and Anterior Cerebral Circulation Infarction

lamotrigine has been researched along with Anterior Cerebral Circulation Infarction in 1 studies

Research Excerpts

ExcerptRelevanceReference
" In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis."9.14Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010)
" In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis."5.14Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kapoor, R1
Furby, J1
Hayton, T1
Smith, KJ1
Altmann, DR1
Brenner, R1
Chataway, J1
Hughes, RA1
Miller, DH1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661]Phase 230 participants (Actual)Interventional2014-10-31Completed
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial[NCT00257855]Phase 2120 participants Interventional2005-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for lamotrigine and Anterior Cerebral Circulation Infarction

ArticleYear
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
    The Lancet. Neurology, 2010, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method

2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
    The Lancet. Neurology, 2010, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method

2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
    The Lancet. Neurology, 2010, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method

2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
    The Lancet. Neurology, 2010, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method

2010